PT-141 Cost and Provider Guide: Compare Bremelanotide Quotes Safely
A source-led PT-141 and bremelanotide cost framework that separates FDA-approved Vyleesi from compounded offers and normalizes prescription, visit, and fulfillment charges.
PeakedLabs editorial standard. We organize provider, pricing, lab-monitoring, and safety signals for research. This is not medical advice; use it to prepare better questions for a licensed clinician.
Executive Summary
PT-141 cost cannot be compared responsibly until the offer identifies the actual product: FDA-approved Vyleesi (bremelanotide injection), a patient-specific compounded preparation, or something marketed outside a legitimate prescription pathway. Those categories do not share the same approval status, evidence, packaging, or oversight.
The current DailyMed Vyleesi label, whose entry lists a revision date of 3/2024, identifies Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women and includes important contraindications and warnings. Uses marketed for men or outside that labeled population are not the FDA-approved indication.
Use the matrix below to compare only written, current quotes. Then review the PT-141 evidence guide and the $29 Complete Peptide Therapy Guide with a licensed clinician before making a treatment decision.
The PeakedLabs guide · $29, one-time
The Complete Peptide Therapy Guide
69 pages on peptide evidence, GLP-1 medicines, provider verification and annual costs. Includes 59 linked sources and eight printable worksheets for your next clinician conversation.
At-a-Glance Comparison
Product-identity and cost-normalization matrix based on the current DailyMed label and FDA compounding guidance. Enter actual quoted amounts; no market average is asserted. Last reviewed September 17, 2026.
| Decision field | Approved Vyleesi path | Compounded offer | What to verify |
|---|---|---|---|
| Product identity | Vyleesi prefilled autoinjector | Exact preparation must be stated | Drug name, strength, dosage form, quantity, manufacturer or pharmacy |
| Regulatory status | FDA-approved labeling applies | Not FDA-approved | Approved indication versus proposed off-label or compounded use |
| Prescription and care | Prescriber and dispensing route | Patient-specific prescription and named pharmacy | Consult, follow-up, and renewal charges |
| Fulfillment | Quoted product quantity and pharmacy terms | Quoted preparation quantity and beyond-use terms | Shipping, supplies, replacement, and refund policy |
| All-in cost | Patient and insurer quote | Clinic and pharmacy quote | Same quantity and time horizon before comparison |
Identify the Product Before Comparing Price
PT-141 is often used as a broad marketing label, while the FDA-approved product is specifically identified as Vyleesi, a bremelanotide injection with defined labeling.
Ask the provider to write down the product name, dosage form, strength, quantity, manufacturer or compounding pharmacy, and proposed indication. Compare that information with the official DailyMed label. Do not assume two offers are equivalent because both use the phrase PT-141.
Common failure mode: a shopper compares one approved autoinjector quote with an unspecified compounded or research product as though they were interchangeable.
Execution Checklist
- Record the exact product and dosage form.
- Record the labeled or proposed use.
- Identify the manufacturer or dispensing pharmacy.
- Reject any quote that will not identify the product.
Normalize Quantity and All-In Cost
A per-device price, vial price, subscription, and consultation package cannot be compared without the same quantity and time horizon.
Use the provider's written quantity and billing terms. Add consultation, prescription review, follow-up, medication, supplies, shipping, and renewal charges. If insurance may apply to an FDA-approved product, request a patient-specific estimate from the insurer and dispensing pharmacy rather than relying on a generic coverage claim.
Common failure mode: a promotional price omits clinician or fulfillment charges, or the compared offers contain different quantities.
Execution Checklist
- Compare the same number of devices or stated treatment period.
- Separate one-time and recurring charges.
- Use patient-specific insurance estimates only.
- Record the quote and verification dates.
Keep Approved, Off-Label, and Compounded Status Visible
Approval belongs to a particular product, indication, dosage form, and labeled population; it does not transfer to every product marketed with the same ingredient name.
FDA states in its compounding Q&A that compounded drugs are not FDA-approved and FDA does not verify their safety, effectiveness, or quality before marketing. Ask the clinician to label the proposed path as approved, off-label, or compounded and explain why it is being considered for you.
Common failure mode: an FDA-approved ingredient claim is used to imply that a different compounded preparation or proposed use is also FDA-approved.
Execution Checklist
- Ask whether the exact product and use are FDA-approved.
- Ask why an approved product would not meet the identified need.
- Verify the pharmacy through its state board.
- Keep marketing claims out of the cost worksheet.
Review Safety and Follow-Up Before Payment
A cost comparison is incomplete when it ignores contraindication screening, adverse-effect counseling, and access to follow-up care.
The current Vyleesi label includes contraindications for uncontrolled hypertension or known cardiovascular disease and warnings about transient blood-pressure increases, focal hyperpigmentation, and nausea. Use the label as a discussion aid, not a self-screening substitute, and ask who handles questions or adverse effects after dispensing.
Common failure mode: the transaction is optimized for checkout while clinical screening, counseling, and follow-up responsibility remain unclear.
Execution Checklist
- Confirm who performs contraindication screening.
- Ask how adverse effects are reported and handled.
- Confirm follow-up access and response expectations.
- Do not purchase products labeled for research use as treatment.
Internal Resources to Compare Next
Use these pages to validate assumptions before spending. Cross-checking provider model details with treatment-specific pages is the fastest way to reduce preventable cost drift in month two and month three.
Compare Providers Before You Purchase
Identify the exact product first, compare an itemized all-in quote second, and use the $29 Complete Peptide Therapy Guide to prepare the clinical and pharmacy questions that price alone cannot answer.
Disclosure: PeakedLabs may earn a commission from partner links. Editorial scoring and rankings remain independent.
Frequently Asked Questions
How much does PT-141 cost?
There is no single reliable price because PT-141 may refer to FDA-approved Vyleesi or to a different compounded offer. Compare the same product identity, quantity, care, and fulfillment terms using current written quotes.
Is PT-141 the same as Vyleesi?
Vyleesi is the FDA-approved bremelanotide injection with specific labeling. PT-141 is often used as a broader name and may describe offers that are not the approved Vyleesi product.
Is PT-141 FDA-approved for men?
The cited Vyleesi label identifies an approved indication in premenopausal women with acquired, generalized HSDD. Use in men is not that FDA-approved indication.
Does insurance cover bremelanotide?
Coverage depends on the exact product, indication, plan, pharmacy network, and authorization rules. Request a patient-specific estimate from the insurer and dispensing pharmacy.
What should a PT-141 provider quote include?
It should identify the exact product, dosage form, strength, quantity, prescriber, pharmacy or manufacturer, consultation and follow-up fees, shipping, supplies, renewal terms, and refund policy.
Are compounded bremelanotide products FDA-approved?
No. FDA states that compounded drugs are not FDA-approved and are not reviewed by FDA before marketing for safety, effectiveness, or quality.
Read next
CJC-1295 + Ipamorelin Cost per Month: Compare the Full Clinic Quote
Normalize any CJC-1295 and ipamorelin clinic quote into the same monthly and six-month cost model before comparing offers.
Peptide Therapy Cost: Build an Honest Monthly and Six-Month Budget
Turn any peptide-clinic quote into a comparable six-month budget and identify missing charges before you pay.
Peptide Therapy Cost Breakdown 2026: What You Will Actually Pay
Model peptide therapy costs in 2026 with realistic low/expected/high scenarios and provider-specific cost controls.
The newsletter
Get the latest peptide & TRT research
Weekly evidence-based updates on protocols, costs, and telehealth provider quality.
Free forever. Unsubscribe anytime. We never sell your email.